Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of NTP42:KVA4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A body mass index (BMI) in the range 18.0-30.0.~* Ability \& willingness to provide written consent.~Exclusion Criteria:~* Clinically relevant abnormal medical history, physical findings, laboratory values at pre-trial screening.~* History of bleeding disorders, coagulation variables or abnormal blood cell count.~* History of chronic illness.~* Impaired endocrine, thyroid, hepatic, renal or respiratory function, diabetes mellitus, coronary heart disease or history of any psychotic mental illness.~* History of adverse reaction or allergy to any drug.~* Use of aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), or any other medicine that affects platelet function or coagulation, or any prescription medicine, during the 28 days before the first dose of trial medication.~* History of drug or alcohol abuse~* Smoker or use of nicotine-containing products~* Blood pressure or heart rate at screening outside normal ranges.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- NTP42:KVA4 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).